Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of Shenqi Sherong Pill in Cervical Spondylotic Myelopathy (Qi Deficiency, Blood Stasis and Kidney Deficiency Type)

NCT06377072 is registered in ClinicalTrials.gov with Shanghai Hutchison Pharmaceuticals Limited as lead sponsor.

NCT NCT06377072
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06377072 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of Shenqi Sherong Pill in Cervical Spondylotic Myelopathy (Qi Deficiency, Blood Stasis and Kidney Deficiency Type)
Lead sponsor
Shanghai Hutchison Pharmaceuticals Limited
Phase
Phase 3
Overall status
Completed
Start date
May 11, 2024
Completion date
January 14, 2026
Enrollment
428 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cervical spondylotic myelopathy